This intrinsic property of AAV to undergo intermolecular ... from a minimal simian virus 40 (SV40) promoter and an increase in expression of 200-fold from the ITR in a vector without a promoter.

Researchers have demonstrated, for the first time in the world using mice, the ability to overcome significant challenges in ...

Potent in vivo gene editing in skeletal muscle of non-human primates by a novel, ultracompact CRISPR system delivered via a single AAV vector.

After endosomal escape, AAVs can also successfully transduce the cell and deliver their viral genome to the nucleus, where the transgene is expressed. Any misfolded protein encoded by the transgene ...

Oxford, UK - 5 February 2025: OXB (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces the ...

(NYSE: BIO and BIO.B), announced the launch of Vericheck ddPCR™ Empty-Full Capsid Kits for adenoassociated virus (AAV) serotypes 2 and 8 ... reproducible data for reliable assessment for critical ...

Researchers are enhancing the best features of AAV capsids and overcoming their limitations to accelerate gene-based therapies.

That therapy uses an adeno-associated virus (AAV) as a vector rather than a lentivirus, a vector type that features in approved gene therapies such as Roche's Luxturna and Novartis' Zolgensma.

Viralgen and Axovia Therapeutics are set to form a partnership to progress the development and manufacturing of an adeno-associated virus vector serotype 9 (AAV9)-based gene therapy for retinal ...

Overall, the findings highlight a need for improved standardization of measurements for AAV in the context of viral vector–based gene therapies, the authors concluded. The study acknowledged the ...